ClinicalTrials.gg
Status unknownNCT05278832Updated Mar 14, 2022

A Study of QLS31905 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of QLS31905 in Advanced Solid Tumors, sponsored by Qilu Pharmaceutical Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-14.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2022), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Oct 2021, registered Feb 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
104
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a multi-center, open-label design to evaluate the safety and tolerance of QLS31905 in patients with advanced solid tumors, together with an assessment of pharmacokinetic characteristics and efficacy.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Qilu Pharmaceutical Co., Ltd. is the lead sponsor of 200 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written .
  2. ≥18 years.
  3. Female or male.
  4. performance status score 0 or 1.
  5. or cytologically confirmed diagnosis of advanced solid tumors.
  6. Adequate haematological, hepatic and renal function.

Exclusion criteria

Exclusion Criteria:

  1. Any anticancer therapy or immunotherapy within 4 weeks prior to the start of study treatment.
  2. Untreated or symptomatic central nervous system (CNS) or .
  3. Patients with a history of monoclonal antibody allergic reaction.
  4. Known infection or known symptomatic hepatitis.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
104 participants (estimated)

Study arms

  • Experimental
    QLS31905

    QLS31905 injection

    Drug: QLS31905

Interventions

06

What researchers measure

Primary outcomes

  1. Dose limiting toxicities(DLTs)

    Number of participants experiencing DLTs According to NCI-CTCAE v.5.0,To evaluate the safety and tolerability of QLS31905

    Time frame: 2 years

  2. Maximum tolerated Dose(MTD)

    To evaluate the safety and tolerability of QLS31905

    Time frame: 2 years

Secondary outcomes

  1. Progression-free Survival (PFS)

    Progression free survival will be determined from investigator derived tumor assessments per RECIST 1.1.

    Time frame: 2 years

  2. Objective response rate (ORR)

    Objective Response Rate (ORR) is the percentage of CR+PR

    Time frame: 2 years

  3. Disease control rate (DCR)

    Disease control Rate (DCR) is the percentage of CR+PR+SD

    Time frame: 2 years

  4. adverse events (AE)

    To evaluate the safety and tolerability of QLS31905

    Time frame: 2 years

  5. Cmax

    Maximum concentration (Cmax) of the drug after administration

    Time frame: 2 years

  6. AUC

    The area under the curve (AUC) of serum concentration of the drug after the administration

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
  • Beijing Cancer Hospital
    Beijing, Beijing 100142, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2021 (actual). Primary completion is estimated for Dec 2022, 14 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2022
First posted
Mar 14, 2022
StartActual
Oct 25, 2021
Primary completionEst.
Dec 31, 2022
CompletionEst.
Dec 31, 2023
Last update
Mar 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05278832
Responsible party
Sponsor
First posted
Mar 14, 2022
Start date
Oct 25, 2021
Primary completion
Dec 31, 2022 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
Mar 14, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905

Start the discussion